Endocrinology

SGLT2 inhibitors not linked to venous thromboembolism in T2D patients

an hour ago

Sodium-glucose co-transporter type 2 (SGLT2) inhibitors do not appear to induce an increased rate of venous thromboembolism in patients with type 2 diabetes as compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, which provides reassurance in terms of the thromboembolic safety of the former, according to a recent study.

No added benefits from weight loss post-ablation for AF patients

Pearl Toh, Yesterday

Undergoing a structured weight loss programme after ablation for atrial fibrillation (AF) does not confer significant reduction in AF burden compared with usual care, according to the SORT-AF* study presented at EHRA 2021.

Socioeconomic status modifies link between air pollution and childhood obesity

6 days ago

Exposure to air pollution in early life appears to contribute to a small increase in the risk of developing overweight or obesity in childhood, with the association more pronounced among children in the most deprived areas, as reported in a study.

Retinal neuronal, axonal layers thinner in diabetic eyes without retinopathy

6 days ago

Even among patients with diabetes mellitus (DM) but no diabetic retinopathy (NDR), thinning of the retinal neuronal and axonal layers is apparent, a recent meta-analysis has found. In turn, this suggests that DR neuropathy (DRN) may be an early marker of clinically detectable DR.

Navigating the CPP patient journey – case-based discussion for nurses

06 May 2021

In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.

Trimetazidine new formulation redefining angina control in daily practice

12 Mar 2021

Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.

Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes

Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Empagliflozin: Another SGLT-2i in HFrEF armamentarium

Roshini Claire Anthony, 05 Nov 2020

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.

The FreeStyle Libre system: A new tool for GPs managing diabetes

26 Oct 2020

An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]

NCDs continue with march in the shadow of COVID-19

Pank Jit Sin, 02 Sep 2020

The most recent report by the National Health and Morbidity Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with consistent, unrelenting efforts by stakeholders and policymakers, the figures for NCDs continue to climb. MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in the country and to obtain his thoughts on the ramifications of the findings.

Empagliflozin advancing on all fronts: Readying for the future with EMPEROR

11 Aug 2020

In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.

BIO89-100 reduces liver fat in NASH

Elaine Soliven, 27 Apr 2021

Weekly (QW) or biweekly (Q2W) treatment with BIO89-100 led to a significantly reduced liver fat and liver fat volume (LFV) in patients with nonalcoholic steatohepatitis (NASH), according to a recent study presented at ENDO 2021.

Ertugliflozin: A suitable add-on for inadequately controlled T2D

Roshini Claire Anthony, 23 Apr 2021

Ertugliflozin may be a suitable add-on therapy in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD) whose glucose levels are inadequately controlled by a metformin-sulfonylurea or insulin regimen, substudies of the phase III VERTIS* CV trial showed.

Male phenotype of PCOS uncovered; risks of T2D, CVD likely

Elvira Manzano, 15 Apr 2021

New evidence from a recent trial points to a genetically defined male equivalent of PCOS* that is characterized by ovarian-independent pathogenesis and can increase risks for excess weight, type 2 diabetes (T2D), and cardiovascular disease (CVD) in men, reports an expert at ENDO 2021.

Patients, doctors to continue using telemedicine postpandemic

Tristan Manalac, 15 Apr 2021

Patients and healthcare practitioners in the endocrinology setting seem satisfied with the use of telemedicine, and most say that they would want to maintain such a system even after the novel coronavirus disease (COVID-19) pandemic, according to a study presented at the recently concluded ENDO 2021 virtual conference by the Endocrine Society.

Abnormal blood sodium levels may indicate COVID-19 severity

Roshini Claire Anthony, 14 Apr 2021

In patients hospitalized with COVID-19, hypernatraemia during hospitalization may increase mortality risk, while hyponatraemia at admission may up the need for ventilation support, a recent study from the UK showed.

Sequential therapy beefs up bone density in women with anorexia

Jairia Dela Cruz, 14 Apr 2021

Administering recombinant human insulin-like growth hormone-1 (rhIGF-1) for 6 months followed by risedronate for another 6 months helps improve bone mineral density (BMD) at the spine in women with anorexia nervosa, according to a study.